301907 VO Development of novel cancer immunotherapies (2020W)
from target identification through target validation to clinical trials
Labels
Registration/Deregistration
Note: The time of your registration within the registration period has no effect on the allocation of places (no first come, first served).
Details
Language: English
Examination dates
- Monday 25.01.2021 09:00 - 11:00 Digital
- Monday 15.03.2021 09:00 - 11:00 Digital
- Tuesday 20.04.2021 09:00 - 11:00 Digital
Lecturers
Classes (iCal) - next class is marked with N
- hybride Lehre -
jeweils 09.00 - 11.00 Uhr
Teil I: 9.,16., 23. und 30. November 2020
Teil II: Vertiefende Vorlesung zu ausgewähltem Immuntherapien
7.12., 14.12., 11.1. und 18.1.2021
- Monday 09.11. 09:00 - 11:00 Digital
- Monday 16.11. 09:00 - 11:00 Digital
- Monday 23.11. 09:00 - 11:00 Digital
- Monday 30.11. 09:00 - 11:00 Digital
- Monday 07.12. 09:00 - 11:00 Digital
- Monday 14.12. 09:00 - 11:00 Digital
- Monday 11.01. 09:00 - 11:00 Digital
- Monday 18.01. 09:00 - 11:00 Digital
Information
Aims, contents and method of the course
Assessment and permitted materials
written exam
Minimum requirements and assessment criteria
100-87%: Sehr Gut ( I ); 87,99-75%: Gut (2); 74,99-62%: Befriedigend (3); 6 I ,99-50%: Genügend (4); < 50%: Nicht Genügend (5)
Examination topics
Reading list
Association in the course directory
MMB IV-2,MMB W-2, MMEI II-3.2,MMEI III, WZB
Last modified: Fr 12.05.2023 00:24
(1) give an overview on current therapies: their potential, their risks and where they currently fail: description of different therapy modalities: Antibodies (check point inhibitors, protacs, T cell engagers , neutralizing Antibodies) and small molecule therapies (inhibitors and agonists)
(2) description on how cancer imrnunotherapy targets are being discovered: available methods for target screening and how to validate them
(3) description how to validate the targets
(4) explain why biomarker research is important for the success oftherapies
(5) describe the different stages of clinical trials